Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 3/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.37 |
| ▸ | IRAK1 | P51617 | 11/20 | 0.36 |
| ▸ | DUT | P33316 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | EDNRB | P24530 | 1/20 | 0.34 |
| ▸ | EDNRA | P25101 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13275328 | 0.94 | MET (0.41) | METNQO2IRAK4IRAK1 | |
| SCHEMBL13275150 | 0.91 | IRAK1 (0.42) | METNQO2IRAK4IRAK1 | |
| SCHEMBL164227 | 0.90 | BRD4 (0.37) | METNQO2IRAK4IRAK1BRD4 | |
| SCHEMBL2221907 | 0.89 | ALKBH1 (0.41) | — | |
| SCHEMBL13274724 | 0.89 | MET (0.37) | METNQO2IRAK4IRAK1 | |
| SCHEMBL255611 | 0.89 | MET (0.41) | MET | |
| SCHEMBL2361889 | 0.88 | IRAK1 (0.49) | METNQO2IRAK4IRAK1 | |
| SCHEMBL2268190 | 0.88 | PPARG (0.37) | METIRAK4IRAK1 | |
| SCHEMBL2223848 | 0.88 | MET (0.48) | METNQO2EDNRBEDNRA | |
| SCHEMBL2363122 | 0.87 | MET (0.34) | METNQO2IRAK4IRAK1EDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | claimed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | claimed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | claimed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | MET 2/4885NQO2 1984/4885IRAK4 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.